CN115590819B - 一种红茴香脂质体、制备方法及其凝胶膏剂 - Google Patents
一种红茴香脂质体、制备方法及其凝胶膏剂 Download PDFInfo
- Publication number
- CN115590819B CN115590819B CN202211247908.3A CN202211247908A CN115590819B CN 115590819 B CN115590819 B CN 115590819B CN 202211247908 A CN202211247908 A CN 202211247908A CN 115590819 B CN115590819 B CN 115590819B
- Authority
- CN
- China
- Prior art keywords
- fennel
- liposome
- red
- organic solvent
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000004204 Foeniculum vulgare Nutrition 0.000 title claims abstract description 115
- 239000002502 liposome Substances 0.000 title claims abstract description 105
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 240000006927 Foeniculum vulgare Species 0.000 title description 2
- 241000212314 Foeniculum Species 0.000 claims abstract description 113
- 229940072117 fennel extract Drugs 0.000 claims abstract description 27
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims abstract description 23
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 22
- 229930182558 Sterol Natural products 0.000 claims abstract description 21
- -1 sterol compound Chemical class 0.000 claims abstract description 21
- 235000003702 sterols Nutrition 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 239000003960 organic solvent Substances 0.000 claims description 41
- 150000002632 lipids Chemical class 0.000 claims description 38
- 238000002390 rotary evaporation Methods 0.000 claims description 36
- 238000002156 mixing Methods 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 238000009210 therapy by ultrasound Methods 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 238000000502 dialysis Methods 0.000 claims description 18
- 239000007762 w/o emulsion Substances 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical group CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 229940032094 squalane Drugs 0.000 claims description 6
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 5
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 5
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 5
- 235000004420 brassicasterol Nutrition 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 150000001647 brassinosteroids Chemical class 0.000 claims 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 34
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract description 16
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract description 16
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 16
- 235000005875 quercetin Nutrition 0.000 abstract description 16
- 229960001285 quercetin Drugs 0.000 abstract description 16
- 239000002245 particle Substances 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 11
- 239000004480 active ingredient Substances 0.000 abstract description 10
- 238000005538 encapsulation Methods 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 239000002674 ointment Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 11
- 229960000913 crospovidone Drugs 0.000 description 10
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 10
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 229940069328 povidone Drugs 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010050031 Muscle strain Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000720991 Illicium Species 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000758724 Schisandraceae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中药制剂技术领域,具体涉及一种红茴香脂质体及其凝胶膏剂。本发明红茴香脂质体包括红茴香提取物、磷脂、甾醇类化合物、琥珀酸二钠。采用脂质体作为红茴香活性成分的载体,优选配方配比,提高了红茴香脂质体的包封率,降低了渗漏率,使其粒径均一、稳定性显著提升。本发明提供的凝胶膏剂提高了活性成分槲皮苷的透皮效率,更有利于其在皮肤及其深层组织持续发挥良好的治疗作用。
Description
技术领域
本发明属于中药制剂技术领域,具体涉及一种红茴香脂质体、制备方法及其凝胶膏剂。
背景技术
红茴香是中国特有的八角属植物,系木兰科八角属植物莽草(Llliciumlanceolatum A.C Smith)干燥的根或茎的皮,其主要分布于海拔300m~2600m的丘陵以及山地湿润常绿阔叶林中。红茴香的根及根皮可入药,主要成分有鞣质、蒽醌、黄酮、有机酸以及挥发油等,其中以槲皮苷为主的黄酮类是其重要成分。红茴香性温,味辛,有毒,具有祛风通络,舒筋活血,散瘀止痛的功效,治疗跌打损伤,腰肌劳损,风湿痹痛,痈疽肿毒,在民间的应用历史悠久,主要用来治疗跌打损伤、腰肌劳损等病症。
以其根皮为原料研发的红茴香注射液现已收载于《中药成方制剂》第二十册,用于腰肌劳损、关节或肌肉韧带伤痛及风湿痛等的治疗。自投放入市场以来,其临床反应效果良好。但这种制剂需要配合穴位注射等方法进行治疗,对患者刺激性较大,同时由于含有莽草酸等有毒物质,较易引起不良反应,影响了该制剂的临床推广。
近年来,已有学者将其制成喷雾剂等经皮给药制剂,中国专利CN102940685 A公开了一种红茴香提取液制备得到的红茴香贴膏剂,包含红茴香提取液、冰片、氮酮、薄荷油、卡波姆、聚乙烯醇、羧甲基纤维素钠、明胶、甘油、水。但槲皮苷等有效成分的透皮效果差,活性成分的透皮效率低,不能发挥出较优的治疗效果。
脂质体由于可通过与表皮脂质融合、促进角质层水化、改变角质细胞间结构以及水和渗透压梯度等作用,因而可促进药物进入皮肤,但又不增加药物进入吸收入血,故可显著提高药物在皮肤及其深层组织的滞留量,对皮肤局部用药有良好的作用。
发明内容
克服现有技术的不足,本发明提供了一种红茴香脂质体,采用脂质体作为红茴香活性成分的载体制备的外用透皮制剂,能够增加活性成分的透皮效率,更有利于其在皮肤及其深层组织持续发挥良好的治疗作用。
具体而言,本发明的技术方案如下:
本发明提供了一种红茴香脂质体,所述红茴香脂质体包括红茴香提取物、磷脂、甾醇类化合物、琥珀酸二钠。
进一步的,所述红茴香脂质体中各组分以重量比计算为:
进一步的,所述磷脂选自磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酸、双磷脂酰甘油中的至少一种,优选为磷脂酰肌醇和硬脂酸。
进一步的,所述甾醇类化合物为胆固醇或/和菜籽甾醇,优选为胆固醇和菜籽甾醇。
进一步的,所述磷脂酰肌醇和硬脂酸的重量比为2-4:1,优选为3:1。
进一步的,所述胆固醇和菜籽甾醇的重量比为2-4:1,优选为3:1。
本发明的第二个目的在于提供一种制备上述红茴香脂质体的方法,所述方法包括以下步骤:
(1)将磷脂、甾醇类化合物与有机溶剂混合溶解,置于烧瓶中水浴30℃-45℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。
进一步的,所述有机溶剂选自甲醇、乙醇、三氯甲烷中的一种,优选为乙醇。
本发明的第三个目的在于提供一种红茴香脂质体凝胶膏剂,所述凝胶膏剂包括权利要求1所述的红茴香脂质体、黏着剂、保湿剂、填充剂、透皮吸收促进剂、药学上可接受的辅料。
进一步的,所述透皮吸收促进剂为角鲨烷。
与现有技术相比,本发明的有益效果在于:
(1)本发明筛选红茴香脂质体的配方,优选配比,尤其是加入了一定比例的琥珀酸二钠,提高了红茴香脂质体的包封率,降低了渗漏率,稳定性显著提升。
(2)本发明进一步利用红茴香脂质体制成凝胶膏剂,优选促进吸收剂,增加了活性成分槲皮苷的透皮效率,更有利于其在皮肤及其深层组织持续发挥良好的治疗作用。
附图说明
图1-3:实施例1-8、对比实施例1-8红茴香脂质体渗漏率情况
图4:(a)实施例1红茴香脂质体粒径大小与分布情况;(b)实施例2红茴香脂质体粒径大小与分布情况;(c)实施例3红茴香脂质体粒径大小与分布情况;(d)对比实施例7红茴香脂质体粒径大小与分布情况。
具体实施方式
为了使本发明的目的、技术方案更加清楚明白,以下结合实施例,对本发明做进一步的说明,但是本发明的保护范围并不限于这些实施例,实施例仅用于解释本发明。本领域技术人员应该理解的是,凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。
一、红茴香提取物的制备
1.红茴香中药效成分的提取
根据红茴香注射液质量标准对红茴香根皮进行提取。
称取3.0g根皮粉末于50ml锥形瓶中,加入30ml 75%乙醇,摇匀使粉末完全没入液面以下,用封口膜封住瓶口,静置7天后,取出,滤过,滤饼用75%乙醇洗涤,合并滤液,减压回收溶剂,加入20ml蒸馏水,超声5分钟后,4000转离心10分钟,取上清液,用10%氢氧化钠溶液调节pH值至约7.0,冷藏过夜,滤过,上清液减压浓缩,真空干燥过夜,得红茴香根皮乙醇浸提物,置于干燥器中,备用。
2.红茴香提取物中活性成分含量的测定
由于黄酮类物质是红茴香的主要活性成分,故红茴香注射剂的质量标准中以芦丁的含量测定为指标,但本研究发现按该法测得的芦丁量会超过乙醇浸提物中所有固体的重量。因此,本方案最终采用了槲皮苷作为红茴香的指标成分,具有更加合理有效。
测定方法:称取20.0mg红茴香提取物于100ml容量瓶中,加蒸馏水定容,4000转离心10分钟,取上清液在350nm处测定吸光值,计算提取率。结果显示槲皮苷含量约为1296mg,占总提取物的20.62%。
二、红茴香脂质体
1.红茴香脂质体及其制备方法
实施例1红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。实施例2红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴40℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。实施例3红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴30℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。实施例4红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与甲醇混合溶解,置于烧瓶中水浴45℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。实施例5红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与三氯甲烷混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。实施例6红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。实施例7红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。实施例8红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。对比实施例1红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。
对比实施例2红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。对比实施例3红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。对比实施例4红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。对比实施例5红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。
对比实施例6红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。
对比实施例7红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。对比实施例8红茴香脂质体及其制备方法
配方:
制备方法:
(1)将磷脂、甾醇类化合物与乙醇混合溶解,置于烧瓶中水浴35℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液、琥珀酸二钠,超声,形成w/o型乳剂,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体凝胶。
2.红茴香脂质体的质量评价
2.1红茴香脂质体包封率测定
2.2.1紫外检测波长的确定
精密称取槲皮苷对照品10.00mg,置于100ml容量瓶中,用甲醇溶解并定容,摇匀后吸取2ml,置于10ml容量瓶中,用甲醇稀释至刻度线,得浓度为20μg·ml-1溶液,在波长200-600nm范围内进行扫描。结果显示槲皮苷在256nm及350nm处有较大吸收,由于脂质在256nm处产生吸收对槲皮苷含量的测定产生干扰,350nm处无干扰,并结合槲皮苷测定相关文献,选择以350nm作为槲皮苷含量测定波长[11-12]。
2.2.2标准曲线绘制
精密配制浓度分别为8、16、32、64、128μg/ml槲皮苷对照品溶液,以纯化水为空白对照,在350nm处测定吸光度。以吸光度A对浓度C进行线性回归,得回归方程:A=6.286C-0.0214,相关系数r=0.9996,槲皮苷在浓度8μg/ml-128μg/ml范围内,线性关系良好。
2.3超滤离心法测定包封率
取2ml红茴香脂质体溶液用无水乙醇破乳后定容至10ml容量瓶中,测定吸光度,代入回归方程得总槲皮苷含量记为m1;另取同一份样品2ml至超滤离心管中,4000转离心10分钟,取滤液定容至10ml容量瓶中,测定吸光度,代入回归方程得游离槲皮苷含量记为m2,脂质体包封率=(m1-m2)/m1×100%。
表1实施例1-8、对比实施例1-8红茴香脂质体包封率
表1为实施例1-8、对比实施例1-8红茴香脂质体的包封率测定结果,显示琥珀酸二钠的加入以及用量、磷脂膜材料的种类等对包封程度有较大影响,本发明实施例1-8制备的红茴香脂质体的包封率高。
2.2红茴香脂质体的稳定性——渗漏率
根据2.1项下的超滤离心法测定,渗漏率=(贮藏后渗漏到介质中的药物量-贮藏前脂质体中包封的药物量)×100%。贮藏条件:置于30℃下,在0d、30d、60d、120d、180d时分别测定,计算红茴香脂质体的渗漏率。
图1-3为实施例1-8、对比实施例1-8红茴香脂质体的渗漏变化情况,结果显示琥珀酸二钠的用量、以及加入的时机等因素对脂质体的渗漏程度有较大影响,本发明实施例1-8制备的红茴香脂质体的渗漏率低,物理稳定性高。
2.3红茴香脂质体粒径
采用马尔文激光纳米粒径测定仪在25℃下测定。
图4中(a)-(d)分别为实施例1、实施例2、实施例3、对比实施例7的红茴香脂质体粒径大小与分布情况,测量到实施例1红茴香脂质体的平均粒径为120.17±1.07nm,实施例2红茴香脂质体的平均粒径为124.16±1.84nm,实施例3红茴香脂质体的平均粒径为126.22±1.26nm,对比实施例7红茴香脂质体的平均粒径为171.54±6.53nm。结果显示本发明实施例制备的红茴香脂质体粒径大小均一。
综上所述,本发明实施例1-8制备得到的红茴香脂质体粒径均一,包封率高,稳定性高,能够为进一步制备制剂提供高质量的保障。
三、红茴香脂质体凝胶膏剂
1.红茴香脂质体凝胶膏剂的制备
实施例9红茴香脂质体凝胶膏剂
称取甘羟铝于研钵中,配研法缓慢加入聚丙烯酸钠,研匀后加入甘油、角鲨烷、实施例1的红茴香脂质体,搅匀备用;另取聚维酮与交联聚维酮于烧杯中,在45℃温度下搅匀后快速加入至上述备用液中,搅匀后缓慢加入含有2%柠檬酸的纯化水,撹匀后,涂布,在50℃下烘干2h,即得红茴香脂质体凝胶膏剂成品。
实施例10红茴香脂质体凝胶膏剂
称取甘羟铝于研钵中,配研法缓慢加入聚丙烯酸钠,研匀后加入甘油、角鲨烷、实施例2的红茴香脂质体,搅匀备用;另取聚维酮与交联聚维酮于烧杯中,在45℃温度下搅匀后快速加入至上述备用液中,搅匀后缓慢加入含有2%柠檬酸的纯化水,撹匀后,涂布,在50℃下烘干2h,即得红茴香脂质体凝胶膏剂成品。
实施例11红茴香脂质体凝胶膏剂
称取甘羟铝于研钵中,配研法缓慢加入聚丙烯酸钠,研匀后加入甘油、角鲨烷、实施例3的红茴香脂质体,搅匀备用;另取聚维酮与交联聚维酮于烧杯中,在45℃温度下搅匀后快速加入至上述备用液中,搅匀后缓慢加入含有2%柠檬酸的纯化水,撹匀后,涂布,在50℃下烘干2h,即得红茴香脂质体凝胶膏剂成品。
对比实施例9
称取甘羟铝于研钵中,配研法缓慢加入聚丙烯酸钠,研匀后加入甘油、角鲨烷、红茴香提取物,搅匀备用;另取聚维酮与交联聚维酮于烧杯中,在45℃温度下搅匀后快速加入至上述备用液中,搅匀后缓慢加入含有2%柠檬酸的纯化水,撹匀后,涂布,在50℃下烘干2h,即得红茴香脂质体凝胶膏剂成品。
对比实施例10
称取甘羟铝于研钵中,配研法缓慢加入聚丙烯酸钠,研匀后加入甘油、实施例3的红茴香脂质体,搅匀备用;另取聚维酮与交联聚维酮于烧杯中,在45℃温度下搅匀后快速加入至上述备用液中,搅匀后缓慢加入含有2%柠檬酸的纯化水,撹匀后,涂布,在50℃下烘干2h,即得红茴香脂质体凝胶膏剂成品。
对比实施例11
中国专利CN 102940685 A说明书中[0041-0046]实施例5红茴香凝胶剂。
对比实施例12
中国专利CN 102940685 A说明书中[0047-0052]实施例6红茴香凝胶剂。
2.红茴香凝胶膏剂的质量检查
根据2020年版《中国药典》第四部中的规定以及其他,对实施例9-11进行外观、含膏量、赋形性、粘附性、微生物限度等考察,结果全部合格。
3.红茴香凝胶膏剂的透皮吸收率
以槲皮苷的累积渗透量为指标,通过透皮吸收试验研究红茴香凝胶膏剂的透皮吸收率。实验动物:SD大鼠,SPF级,180-220g,实验动物许可证号:SYXK(鲁)2018 0008,实验前适应性饲养一周。
离体鼠皮的制备:用8%硫化钠溶液将大鼠脱毛,洗净后,再将动物饲养24h,断颈处死后取腹部皮肤,去除皮下脂肪,用生理盐水反复洗净,滤纸吸去表面水分,备用。
体外透皮试验:将大鼠皮肤固定在接受池与供给池之间,供给池分别精密量取等体积的实施例9-11红茴香脂质体凝胶膏剂、对比实施例9-12红茴香凝胶膏剂均匀涂抹于皮肤上,涂抹面积、时间相同,皮肤角质层朝上,接受池内生理盐水为接受液,且接受液与皮肤真皮层刚好接触,置于(37±0.5)℃恒温水浴中,以200r/min的转速搅拌。分别于2、4、8、12、24h取样5mL,同时补充等体积的生理盐水。取出的接受液微孔滤膜过滤,进样20μL,记录峰面积,计算槲皮苷浓度,并计算累积渗透量(Q)。
其中V为接受液总体积,Cn为第n个取样点测得的药物浓度(μg/mL),C为第i个取样点测得的药物浓度(μg/mL),V为取样体积,A为扩散渗透面积(cm2)。
表2透皮吸收实验结果
通过表2显示,本发明红茴香脂质体凝胶膏剂可以增加活性成分槲皮苷的透皮效率,更有利于其在皮肤及其深层组织持续发挥良好的治疗作用。
Claims (7)
1.一种红茴香脂质体,其特征在于,所述红茴香脂质体中各组分以重量比计算为:
红茴香提取物 50-100份
磷脂酰肌醇和硬脂酸 20-200份
胆固醇和菜籽甾醇 10-100份
琥珀酸二钠 1-8份;
所述磷脂酰肌醇和硬脂酸的重量比为2-4:1;
所述胆固醇和菜籽甾醇的重量比为2-4:1;
所述红茴香提取物的制备方法为:
称取3.0g红茴香根皮粉末于50ml锥形瓶中,加入30ml 75%乙醇,摇匀使粉末完全没入液面以下,用封口膜封住瓶口,静置7天后,取出,滤过,滤饼用75%乙醇洗涤,合并滤液,减压回收溶剂,加入20ml蒸馏水,超声5分钟后,4000转离心10分钟,取上清液,用10%氢氧化钠溶液调节pH值至7.0,冷藏过夜,滤过,上清液减压浓缩,真空干燥过夜,得到红茴香提取物;
所述红茴香脂质体的制备方法为:
(1)将磷脂、甾醇类化合物与有机溶剂混合溶解,置于烧瓶中水浴30℃-45℃减压旋蒸去除有机溶剂,形成脂质薄膜;
(2)向步骤(1)制备的脂质薄膜中加入红茴香提取物水溶液,超声,形成w/o型乳剂,加入琥珀酸二钠,混合,减压旋蒸、透析去除有机溶剂,得到红茴香脂质体。
2.根据权利要求1所述的红茴香脂质体,其特征在于,所述磷脂酰肌醇和硬脂酸的重量比为3:1。
3.根据权利要求1所述的红茴香脂质体,其特征在于,所述胆固醇和菜籽甾醇的重量比为3:1。
4.根据权利要求1所述的红茴香脂质体,其特征在于,所述有机溶剂选自甲醇、乙醇、三氯甲烷中的一种。
5.根据权利要求1所述的红茴香脂质体,其特征在于,所述有机溶剂为乙醇。
6.一种红茴香脂质体凝胶膏剂,其特征在于,所述凝胶膏剂包括权利要求1所述的红茴香脂质体和药学上可接受的辅料。
7.根据权利要求6所述的红茴香脂质体凝胶膏剂,其特征在于,还含有透皮吸收促进剂,所述的透皮吸收促进剂为角鲨烷。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211247908.3A CN115590819B (zh) | 2022-10-12 | 2022-10-12 | 一种红茴香脂质体、制备方法及其凝胶膏剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211247908.3A CN115590819B (zh) | 2022-10-12 | 2022-10-12 | 一种红茴香脂质体、制备方法及其凝胶膏剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115590819A CN115590819A (zh) | 2023-01-13 |
CN115590819B true CN115590819B (zh) | 2024-02-02 |
Family
ID=84846569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211247908.3A Active CN115590819B (zh) | 2022-10-12 | 2022-10-12 | 一种红茴香脂质体、制备方法及其凝胶膏剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115590819B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102940685A (zh) * | 2012-11-14 | 2013-02-27 | 中国人民解放军南京军区南京总医院 | 红茴香提取液及含有红茴香提取液的外用透皮吸收制剂 |
CN103735509A (zh) * | 2013-12-27 | 2014-04-23 | 上海新亚药业有限公司 | 一种米铂脂质体及其制备方法 |
WO2021110173A1 (en) * | 2019-12-06 | 2021-06-10 | Anovent Pharmaceuticals Co., Ltd | Liposome formulation of fluticasone propionate |
-
2022
- 2022-10-12 CN CN202211247908.3A patent/CN115590819B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102940685A (zh) * | 2012-11-14 | 2013-02-27 | 中国人民解放军南京军区南京总医院 | 红茴香提取液及含有红茴香提取液的外用透皮吸收制剂 |
CN103735509A (zh) * | 2013-12-27 | 2014-04-23 | 上海新亚药业有限公司 | 一种米铂脂质体及其制备方法 |
WO2021110173A1 (en) * | 2019-12-06 | 2021-06-10 | Anovent Pharmaceuticals Co., Ltd | Liposome formulation of fluticasone propionate |
Non-Patent Citations (2)
Title |
---|
红茴香脂质体凝胶膏剂的研制;丁敏;中国优秀硕士学位论文全文数据库;E057-33 * |
纳米技术在改善中药有效成分成药性中的应用;高彩芳;中草药(12);31-39 * |
Also Published As
Publication number | Publication date |
---|---|
CN115590819A (zh) | 2023-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101961422B (zh) | 普洱茶提取物及其制备 | |
CN107028919B (zh) | 一种复方七叶皂苷a、b脂质体水凝胶贴剂 | |
CN101961375B (zh) | 普洱茶的提取物及其制备方法 | |
CN101961426B (zh) | 普洱茶的提取物及提取方法 | |
CN112022919A (zh) | 经皮吸收的苍艾油传递体凝胶及其制备方法 | |
CN101961424B (zh) | 普洱茶的提取物及其制备 | |
CN113133956B (zh) | 一种用于抗皮肤衰老的瓜拉纳丁香精油复合纳米乳 | |
CN115590819B (zh) | 一种红茴香脂质体、制备方法及其凝胶膏剂 | |
CN102133245B (zh) | 降低蛋白质含量的鸦胆子油及其药物组合物以及它们的制备方法 | |
CN110227062B (zh) | 一种黄芩苷脂质体软膏及其制备方法 | |
JP3814419B2 (ja) | 脂肪分解促進剤および痩身用皮膚化粧料 | |
CN101961423B (zh) | 普洱茶提取物及其制备方法 | |
CN108653133A (zh) | 一种玉米须黄酮抗氧化凝胶剂的制备方法 | |
CN110812249B (zh) | 一种光甘草定立方液晶纳米粒及其抗皮肤光损伤的应用 | |
CN107252431B (zh) | 一种复方七叶皂苷a脂质体水凝胶贴剂 | |
CN110893204A (zh) | 一种丁香复方水凝胶及其制备方法 | |
CN111281851A (zh) | 一种具有祛痘功效的pH靶向柔性纳米脂质体及其制备方法 | |
CN113144220B (zh) | β-环糊精包合物、凝胶制剂及其制备方法与应用 | |
Mu et al. | Transdermal permeation research of ethanol extracts from Lycopodium clavatum | |
CN116270472B (zh) | 一种依巴斯汀脂质体微针制剂及其制备方法和应用 | |
CN115501211B (zh) | 一种中药痛风贴及其制备方法 | |
CN114699439B (zh) | 一种具有抗炎作用的五味甘露自发热凝胶贴及其制备方法 | |
CN109985075B (zh) | 一种银杏叶提取物注射液及其制备方法 | |
CN117257852A (zh) | 一种积雪草总苷脂质体凝胶剂及其制备方法和抗皮肤癌应用 | |
CN116725952A (zh) | 一种米诺地尔搽剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |